FORMULATION OF MESALAMINE-LOADED RECTAL MUCOADHESIVE PELLETS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE USING 32FULL FACTORIAL DESIGN

PAYAL N. VAJA; CHETAN M. DETROJA

doi:10.22159/ijap.2022v14i5.45180

Authors

PAYAL N. VAJA Department of Pharmaceutics, School of Pharmacy, R. K. University, Rajkot, Gujarat 360020, India https://orcid.org/0000-0003-4598-2944
CHETAN M. DETROJA Department of Pharmaceutics, School of Pharmacy, R. K. University, Rajkot, Gujarat 360020, India https://orcid.org/0000-0001-7855-2671

DOI:

https://doi.org/10.22159/ijap.2022v14i5.45180

Keywords:

Inflammatory bowel disease, Extrusion, Spheronization, Suppository, Sustained release, Mucoadhesion

Abstract

Objective: The objective of the present work was to optimize a rectal suppository containing mucoadhesive pellets of Mesalamine to achieve local yet sustained release of Mesalamine for once-a-day administration for the therapy of Inflammatory Bowel Disease.

Methods: Thus, the present work involves forming mucoadhesive pellets of mesalamine by extrusion spheronization, which were then loaded into a suppository to be administered rectally. The pellets were evaluated for mucoadhesion strength, swelling potential, morphology, particle size, drug release, drug loading and retention time.

Results: The optimized batch of pellets using Eudragit RLPO as the release retardant, carrageenan as a mucoadhesive polymer and other excipients had a mucoadhesion strength of 0.143 N, a swelling index of 50.50 %, and 44 % and 75 % drug was released from them at the end of 6 and 15 h respectively. The pellets-loaded cocoa butter suppositories had a melting range of 35–37 °C, disintegrated within 8–9 min and had a hardness of 4–5 kg/cm³. A comparison of the in vitro drug release profile from the mucoadhesive pellets and the mucoadhesive pellets-loaded suppositories showed a closeness in the % cumulative drug release indicating that cocoa butter did not interfere in the release of the drug from the pellets.

Conclusion: Mucoadhesive Pellets were successfully developed by extrusion spheronizer technique and incorporated into suppositories. In vitro study revealed a release profile that warranted a once-a-day regimen leading to a reduction in the requirement of the drug and hence the side effects.

Downloads

Download data is not yet available.

References

Podolsky DK. Inflammatory bowel disease (1). N Engl J Med. 1991 Sep 26;325(13):928-37. doi: 10.1056/NEJM199109263251306, PMID 1881418.

Lennard Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989 Jan 1;Suppl 170:2-6. doi: 10.3109/00365528909091339, PMID 2617184.

Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007 May 12;369(9573):1627-40. doi: 10.1016/S0140-6736(07)60750-8, PMID 17499605.

Moura FA, Goulart MOF. Inflammatory bowel diseases: the crosslink between risk factors and antioxidant therapy. In: Chapter 7. Gastrointestinal tissue [internet] Gracia-Sancho J, Salvadó J, editors, Academic Press; 2017. p. 99-112.

Akbar A, Arnott I, Kennedy NA, Nolan J, Peake S, Whiteoak SR. Recommendations for the optimal use of mesalazine in the management of patients with mild to moderate ulcerative colitis. Br J Hosp Med (Lond). 2021 Oct 2;82(10):1-11. doi: 10.12968/hmed.2021.0399, PMID 34726945.

Baig MMA, Fatima S, Fatima M, Siddiqui S, Ali SA, Ilyas MN. Prescription pattern and cost of illness (CoI) of inflammatory bowel disease (IBD) in a tertiary care hospital. Int J Pharm Pharm Sci. 2017 Jan 1;9(1):44-7.

Nakashima J, Preuss CV. Mesalamine (USAN). In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2021. Available from: http://www.ncbi.nlm.nih.gov/books/NBK551714/. [Last accessed on 2021 Dec 31]

Schroeder KW. Is mesalamine safe? Gastroenterol Hepatol (NY). 2007 Nov;3(11):878-9. PMID 21960801.

Harris MS, Lichtenstein GR. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2011 May;33(9):996-1009. doi: 10.1111/j.1365-2036.2011.04619.x, PMID 21385194.

Asghar LF, Chandran S. Multiparticulate formulation approach to colon-specific drug delivery: current perspectives. J Pharm Pharm Sci. 2006;9(3):327-38. PMID 17207416.

Singh I, Devi G, Barik BR, Sharma A, Kaur L. Mucoadhesive pellets for drug delivery applications: a critical review. Rev Adhes Adhesives 2020;8(2):153-67. doi: 10.7569/RAA.2020.097305.

B JJ, Doniparthi J. Multiparticulate drug delivery systems using natural polymers as release retardant materials. Int J Pharm Pharm Sci. 2014 Oct 1;6(10):61-5.

Rabiskova M, Bautzova T, Gajdziok J, Dvorackova K, Lamprecht A, Pellequer Y. Coated chitosan pellets containing rutin intended for the treatment of inflammatory bowel disease: in vitro characteristics and in vivo evaluation. Int J Pharm. 2012 Jan 17;422(1-2):151-9. doi: 10.1016/j.ijpharm.2011.10.045, PMID 22079717.

MRD, Ruby JJ. Formulation and evaluation of acarbose pellets by extrusion spheronization technique. Int J Curr Pharm Res. 2020 Nov 15;12(6):67-73.

Komati S, Swain S, Rao MEB, Jena BR, Unnam S, Dasi V. QbD-based design and characterization of mucoadhesive microspheres of quetiapine fumarate with improved oral bioavailability and brain biodistribution potential. Boll Fac Pharm. Cairo University. 2018 Dec 1.

Song L, Liang L, Shi X, Chen H, Zhao S, Chen W. Optimizing pH-sensitive and time-dependent polymer formula of colonic pH-responsive pellets to achieve precise drug release. Asian J Pharm Sci. 2019 Jul 1;14(4):413-22. doi: 10.1016/j.ajps.2018.05.012, PMID 32104470.

Amin MJ, Patel KS, Patel DR, Patel ZP, Bajag JV. Formulation and evaluation of sustained-release pellets of lornoxicam. Int J App Pharm. 2021 Jul 7:221-7. doi: 10.22159/ijap.2021v13i4.41601.

Kumar BP, Chandiran IS, Jayaveera KN. Formulation development and evaluation of glibenclamide loaded Eudragit RLPO microparticles. Int Curr Pharm J. 2013 Nov 14;2(12):196-201. doi: 10.3329/icpj.v2i12.17016.

Pachpute T, Dwivedi J, Shelke T, Jeyabalan G. Formulation and evaluation of mesalamine nanosphere tablet. J Drug Deliv Ther. 2019;9(4):1045-53.

Borra S, Eswaraiah M, Reddy G. Formulation and in vitro/in vivo evaluation of control targeted-release budesonide multi-unit pellet tablets for colon targeting. Asian J Pharm. 2017;11(4):955-65.

Rasenack N, Steckel H, Muller BW. Micronization of anti-inflammatory drugs for pulmonary delivery by a controlled crystallization process. J Pharm Sci. 2003 Jan 1;92(1):35-44. doi: 10.1002/jps.10274, PMID 12486680.

Shalaby K, M Samy A, Kassem A, F Ibrahim M, K Alruwaili N, M Ali H. Formulation, in vitro and bioavailability assessments of ranitidine rectal suppositories. J Pharm Res Int. 2019 Oct 10:1-10. doi: 10.9734/jpri/2019/v30i130262.

Baviskar P, Jaiswal S, Sadique S, Landged A. Formulation and evaluation of lornoxicam suppositories. J Pharm Innov. 2013;2(7):20-8.

Hargoli S, Farid J, Azarmi SH, Ghanbarzadeh S, Zakeri Milani P. Preparation and in vitro evaluation of naproxen suppositories. Indian J Pharm Sci. 2013;75(2):143-8. PMID 24019561.

Sankar R, Reddy YD, Reddy G, Reddy G. Formulation and in vitro characterisation of sustained release metronidazole cocoa butter suppositories. Inventi J. 2012 Oct 15;2012(4):275-80.

Nicoara A, Cazacincu R, Lupuliasa D, Miron D, Radulescu F. Formulation and in vitro release testing of rectal suppositories containing nimesulide. Farmacia. 2015;63(1):111-7.

Saleem MA, Taher M, Sanaullah S, Najmuddin M, Ali J, Humaira S. Formulation and evaluation of tramadol hydrochloride Rectal Suppositories. Indian J Pharm Sci. 2008;70(5):640-4. doi: 10.4103/0250-474X.45405, PMID 21394263.

Hammouda YE, Kasim NA, Nada AH. Formulation and in vitro evaluation of verapamil HCl suppositories. International Journal of Pharmaceutics. 1993 Jan 15;89(2):111-8. doi: 10.1016/0378-5173(93)90111-R.

Muley SS, Nandgude T, Poddar S. Formulation and optimization of lansoprazole pellets using factorial design prepared by an extrusion-spheronization technique using carboxymethyl tamarind kernel powder. Recent Pat Drug Deliv Formul. 2017;11(1):54-66. doi: 10.2174/1872211311666170113150248, PMID 28088896.

Veerubhotla K, Walker RB. Application of quality by design principles for optimizing process variables of extrusion and spheronization of a captopril pellet formulation. Indian J Pharm Sci. 2020 Feb 29;82(1):76-84. doi: 10.36468/pharmaceutical-sciences.624.

Ruíz G, Ghaly ES. Mucoadhesive delivery systems using carrageenan and Eudragit RLPO. Vitae. 2006;13(1).

Gandhi A, Jana S, Sen KK. In vitro release of acyclovir-loaded Eudragit RLPO(®) nanoparticles for sustained drug delivery. Int J Biol Macromol. 2014 Jun;67:478-82. doi: 10.1016/j.ijbiomac.2014.04.019, PMID 24755259.

Mehta R, Chawla A, Sharma P, Pawar P. Formulation and in vitro evaluation of Eudragit S-100 coated naproxen matrix tablets for colon-targeted drug delivery system. J Adv Pharm Technol Res. 2013;4(1):31-41. doi: 10.4103/2231-4040.107498, PMID 23662280.

Srujan Kumar M, Das B, Raju S. Formulation and evaluation of multiunit pellet system of venlafaxine hydrochloride. J Pharm Biomed Sci. 2012;18(18):1-12.

Wan LSC, Heng PWS, Liew CV. Spheronization conditions on spheroid shape and size. International Journal of Pharmaceutics. 1993 Jul 31;96(1-3):59-65. doi: 10.1016/0378-5173(93)90212-X.

Ham AS, Buckheit RW. Designing and developing suppository formulations for anti-HIV drug delivery. Ther Deliv. 2017 Sep;8(9):805-17. doi: 10.4155/tde-2017-0056, PMID 28825395.

Reddy RS, Kumar L, Pydi CR, Reddy MS, Verma R. Development of fluconazole suppositories for the treatment of candida infection of genitourinary tract. Indian J Pharm Educ Res. 2018;52(4s):s16-22. doi: 10.5530/ijper.52.4s.71.

Bartels DA, Johnson R, Bayor MT, Ainooson GK, Ossei PPS, Etuaful RK. Formulation of suppositories of alum produced from bauxite waste in ghana for the treatment of hemorrhoid. Scientific World Journal. 2021;2021:6667562. doi: 10.1155/2021/6667562. PMID 34093089.